Naruse 1982.

Methods	Cross‐over trial of pimozide versus haloperidol versus placebo
Participants	87 children (3‐16 years), 69 boys and 18 girls from 12 hospitals; 34 with autistic disturbance, 27 with behaviour disturbance caused by organic damage, 17 with mental retardation, 5 with neurosis and 4 with psychosis Location/setting: 12 hospitals in Germany Sample size: 87 Number of withdrawals/dropouts: not reported (unable to obtain full text) Gender: 69 boys, 18 girls Mean age: 3‐16 years IQ: not reported Concurrent medications: not reported History of previous medications: not reported Baseline ABC‐I or other BoC: not reported
Interventions	Intervention 1 (pimozide) for 8 weeks: the initial dose was pimozide 1 tablet (1 mg). The maximum daily dose was 9 tablets (pimozide 9 mg). Intervention 2 (haloperidol) for 8 weeks: 1 tablet (0.75 mg). The maximum daily dose was 9 tablets (haloperidol 6.75 mg). Comparator (placebo) for 8 weeks: equivalent placebo
Outcomes	Primary outcomes: anger/aggression/injury and violence to others Secondary outcomes: none reported Timing of outcome assessments: not reported
Notes	Study start date: not reported Study end date: not reported Source of funding: not reported Conflicts of interest: not reported Comment: not able to obtain the full text